Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.66 by 7.83 percent. This is a 38.76 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $119.222 million which missed the analyst consensus estimate of $121.061 million by 1.52 percent. This is a 24.14 percent increase over sales of $96.042 million the same period last year.